A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Usnoflast (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms UNITE-ALS
- Sponsors Zydus Lifesciences
Most Recent Events
- 05 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2025 Status changed from not yet recruiting to recruiting.
- 22 Jan 2025 According to a Zydus Lifesciences media release, company has recently received approval from USFDA to initiate this study.